INVESTOR ALERT: Investigation of Lipocine Inc. Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Lipocine Inc. (“Lipocine” or the
“Company”) (NASDAQ: LPCN) concerning the Company and its officers’ possible violations of federal securities laws.
Lipocine is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in
the areas of men’s and women’s health.
On June 29, 2016, Lipocine disclosed that it received a Complete Response Letter (“CRL”) from the United States Food and Drug
Administration (“FDA”) concerning its New Drug Application (“NDA”) for LPCN 1021, a drug candidate for testosterone replacement
therapy ("TRT"). In the CRL, the FDA identified deficiencies related to the dosing algorithm for the label and informed the Company
that an application could not be approved in its present form.
On this news, shares of Lipocine have fallen sharply, over 51% to just $3.01 per share during intra-day trading on June 29,
2016.
If you purchased Lipocine securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160706005426/en/